Howe & Rusling’s Oncolytics Biotech ONCY Stock Holding History

Howe & Rusling’s Portfolio ONCY Stock Details ONCY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-105	Closed	–	–	807
2022 Q3	$0	Hold	105	–	–	﹤0.01%	1155
2022 Q2	$0	Hold	105	–	–	﹤0.01%	1133
2022 Q1	$0	Hold	105	–	–	﹤0.01%	1060
2021 Q4	$0	Hold	105	–	–	﹤0.01%	1048
2021 Q3	$0	Hold	105	–	–	﹤0.01%	1017
2021 Q2	$0	Hold	105	–	–	﹤0.01%	1005
2021 Q1	$0	Hold	105	–	–	﹤0.01%	995
2020 Q4	$0	Hold	105	–	–	﹤0.01%	984
2020 Q3	$0	Hold	105	–	–	﹤0.01%	852
2020 Q2	$0	Hold	105	–	–	﹤0.01%	874
2020 Q1	$0	Hold	105	–	–	﹤0.01%	844
2019 Q4	$0	Hold	105	–	–	﹤0.01%	859
2019 Q3	$0	Hold	105	–	–	﹤0.01%	854
2019 Q2	$0	Hold	105	–	–	﹤0.01%	864
2019 Q1	$0	Hold	105	–	–	﹤0.01%	864
2018 Q4	$0	Hold	105	–	–	﹤0.01%	878
2018 Q3	$0	Hold	105	–	–	﹤0.01%	890
2018 Q2	$1K	Buy	+105	New	+$646	﹤0.01%	763

Other funds holding ONCY

IAIM

International Assets Investment Management Orlando, Florida $1.67B AUM 28.26% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Howe & Rusling's ONCY Position: Q4 2022 in Review

Howe & Rusling sold out of Oncolytics Biotech (ONCY) in Q4 2022, closing a stake of 105 shares.

Howe & Rusling first reported a position in ONCY in Q2 2018 and held it in 18 quarters. The position peaked at $1K in Q2 2018. 35 funds tracked by Wall St. Rank hold ONCY as of Q4 2022.

Howe & Rusling reported no remaining Oncolytics Biotech position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 105 Oncolytics Biotech shares in Q4 2022.
Howe & Rusling first reported a position in Oncolytics Biotech in Q2 2018 and held it in 18 quarters.
Howe & Rusling's Oncolytics Biotech position peaked at $1K in Q2 2018.
35 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.